Group One Trading’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.95M | Buy |
549,300
+87,700
| +19% | +$1.38M | 0.01% | 1307 |
|
|
2025
Q4 | $8.42M | Sell |
461,600
-208,700
| -31% | -$3.52M | 0.01% | 1063 |
|
|
2025
Q3 | $9.83M | Buy |
670,300
+6,300
| +0.9% | +$108K | 0.02% | 913 |
|
|
2025
Q2 | $12.1M | Sell |
664,000
-17,300
| -3% | -$353K | 0.03% | 693 |
|
|
2025
Q1 | $13.5M | Buy |
681,300
+13,100
| +2% | +$227K | 0.04% | 476 |
|
|
2024
Q4 | $11.5M | Buy |
668,200
+89,600
| +15% | +$1.69M | 0.03% | 625 |
|
|
2024
Q3 | $11.6M | Buy |
578,600
+232,800
| +67% | +$3.62M | 0.03% | 540 |
|
|
2024
Q2 | $3.87M | Buy |
345,800
+135,800
| +65% | +$1.14M | 0.02% | 970 |
|
|
2024
Q1 | $1.39M | Buy |
210,000
+168,500
| +406% | +$921K | 0.01% | 1806 |
|
|
2023
Q4 | $188K | Buy |
41,500
+9,800
| +31% | +$36.3K | ﹤0.01% | 3924 |
|
|
2023
Q3 | $113K | Sell |
31,700
-284,600
| -90% | -$1.1M | ﹤0.01% | 4337 |
|
|
2023
Q2 | $1.17M | Buy |
316,300
+180,700
| +133% | +$670K | ﹤0.01% | 2219 |
|
|
2023
Q1 | $449K | Sell |
135,600
-521,400
| -79% | -$1.8M | ﹤0.01% | 2881 |
|
|
2022
Q4 | $2.55M | Buy |
657,000
+63,400
| +11% | +$196K | 0.01% | 1627 |
|
|
2022
Q3 | $1.44M | Buy |
593,600
+226,200
| +62% | +$543K | ﹤0.01% | 2199 |
|
|
2022
Q2 | $727K | Buy |
367,400
+201,000
| +121% | +$395K | ﹤0.01% | 3065 |
|
|
2022
Q1 | $305K | Sell |
166,400
-39,400
| -19% | -$61.5K | ﹤0.01% | 4349 |
|
|
2021
Q4 | $290K | Sell |
205,800
-9,700
| -5% | -$12.8K | ﹤0.01% | 4696 |
|
|
2021
Q3 | $244K | Sell |
215,500
-44,200
| -17% | -$61.9K | ﹤0.01% | 4959 |
|
|
2021
Q2 | $416K | Sell |
259,700
-198,600
| -43% | -$349K | ﹤0.01% | 4428 |
|
|
2021
Q1 | $807K | Buy |
458,300
+172,800
| +61% | +$395K | ﹤0.01% | 3492 |
|
|
2020
Q4 | $557K | Sell |
285,500
-133,900
| -32% | -$281K | ﹤0.01% | 3165 |
|
|
2020
Q3 | $1M | Buy |
419,400
+76,400
| +22% | +$210K | ﹤0.01% | 2192 |
|
|
2020
Q2 | $1M | Sell |
343,000
-42,700
| -11% | -$123K | ﹤0.01% | 2010 |
|
|
2020
Q1 | $1.11M | Buy |
385,700
+371,400
| +2,597% | +$1.28M | 0.01% | 1451 |
|
|
2019
Q4 | $57K | Sell |
14,300
-45,600
| -76% | -$199K | ﹤0.01% | 3940 |
|
|
2019
Q3 | $267K | Buy |
59,900
+44,500
| +289% | +$186K | ﹤0.01% | 2867 |
|
|
2019
Q2 | $60K | Buy |
+15,400
| New | +$68K | ﹤0.01% | 3674 |
|
|
2019
Q1 | – | Sell |
-1,000
| Closed | -$2K | – | 4727 |
|
|
2018
Q4 | $2K | Hold |
1,000
| – | – | ﹤0.01% | 4635 |
|
|
2018
Q3 | $5K | Buy |
+1,000
| New | +$5.76K | ﹤0.01% | 4815 |
|
Other funds holding ADMA
VCM
VPM
N
Group One Trading's ADMA Position: Q1 2026 in Review
Group One Trading reduced its ADMA Biologics (ADMA) stake by 63% in Q1 2026, selling an estimated $1.91M and leaving 70,183 shares worth $632K. The position accounts for ﹤0.01% of the portfolio, ranked #3125.
Group One Trading first reported a position in ADMA in Q3 2018 and has held it in 17 quarters since. The position peaked at $3.49M in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.
- Group One Trading held 70,183 shares of ADMA Biologics worth $632K as of Q1 2026.
- Group One Trading sold 121,081 ADMA Biologics shares in Q1 2026, an estimated $1.91M.
- ADMA Biologics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #3125 holding.
- Group One Trading first reported a position in ADMA Biologics in Q3 2018 and has held it in 17 quarters since.
- Group One Trading's ADMA Biologics position peaked at $3.49M in Q4 2025.
- 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.